Zuo Jinming,Wang Qingwei,Zhu Wen,et al.Efficacy and safety of detrusor and external urethral sphincter injections of botulinum toxin A in children with detrusor overactivity and impaired contractility[J].Journal of Clinical Pediatric Surgery,,():348-354.[doi:10.3760/cma.j.cn101785-202403060-009]
Efficacy and safety of detrusor and external urethral sphincter injections of botulinum toxin A in children with detrusor overactivity and impaired contractility
- Keywords:
- Urinary Bladder; Overactive; Botulinum Toxins; IInjections; Intramuscular; Treatment Outcome; Child
- Abstract:
- Objective To assess the efficacy and safety of detrusor and external urethral sphincter injections of botulinum toxin A in children with detrusor overactivity and impaired contractility (DOIC). Methods From May 2022 to June 2023,a total of 25 DOIC children received injections of botulinum toxin A in detrusor and external urethral sphincter.There were 18 boys and 7 girls with a mean age of (11.0±3.8) year.Three-day voiding diaries,quality of life questionnaires and incontinence-specific quality of life (I-QOL) assessments and overactive bladder symptom score (OABSS) were completed at baseline and Month 1/6.Also video-urodynamic examination at baseline and Month 1 and free uroflowmetry and residual urine measurement at baseline and Month 6 were performed.And the occurrences of adverse events were recorded. Results At baseline,mean urinary incontinence episode and daily voiding frequency were (6.9±1.5) and (10.8±1.7),quality of life questionnaire (8.8±0.7),OABSS (10.5±1.8),I-QOL score (43.6±4.6),mean voiding volume (127.4±37.9) ml,functional bladder capacity (FBC) (160.7±29.4) ml,maximum flow rate (MFR) (9.7±3.3) ml/s,mean daily frequency of catheterization (8.0±0.5),postvoid residual (PVR) (190.6±99.2) ml and bladder emptying efficiency (32.8±4.9)% in children undergoing intermittent catheterization (IC).At Month 1/6 post-injection,mean urinary incontinence episode and daily voiding frequency decreased to (3.5±1.3),(4.9±1.4) and (7.6±1.1),(8.5±1.4); quality of life questionnaire declined to (5.8±0.9),(7.1±0.8); OABSS score dropped to (8.5±1.0),(9.0±1.3); mean daily frequency of catheterization dipped to (6.4±0.7),(7.3±0.8),PVR decreased to (91.3±36.7),(121.9±42.7) ml; I-QOL score jumped to (59.7±5.8),(50.1±4.7); mean voiding volume increased to (164.9±31.1),(146.0±24.5) ml; FBC rose to (198.3±27.5),(176.2±24.3) ml; MFR spiked to (13.8±3.1),(11.0±2.5) ml/s; bladder emptying efficiency increased to (62.0±6.4),(47.8±6.7)%; Furthermore,the results of video-urodynamic examinations were compared between Month 1 and baseline.Maximum cystometric bladder capacity (MCC)(230.2±36.0 vs. 198.2±46.1 ml) and bladder compliance (BC)(18.6±5.1 vs.14.4±6.6 ml/cmH2O) increased.In addition,maximal detrusor pressure (64.4±6.0 vs.80.0±5.1 cmH2O) and frequency of DO during bladder filling period (2.8±1.3 vs.4.4±1.7),maximum urethral pressure (MUP)(72.0±5.5 vs.78.5±8.2 cmH2O) and maximum urethral closure pressure (MUCP)(59.1±5.2 vs.64.1±7.2 cmH2O) all decreased.Among 4 children of vesicoureteral reflux (VUR) at baseline,there were resolution (n=2) and improvement (n=2) at Month 1; 5/11 children of detrusor external sphincter dyssynergia (DESD) at baseline resolved at Month 1; 2/7 children of detrusor bladder neck dyssynergia (DBND) at baseline resolved at Month 1.Furthermore,as compared with Month 1,mean urinary incontinence episode (4.9±1.4 vs. 3.5±1.3) and daily voiding frequency (8.5±1.4 vs. 7.6±1.1),quality of life questionnaire (7.1±0.8 vs. 5.8±0.9),mean daily frequency of catheterization (7.3±0.8 vs. 6.4±0.7) and PVR (121.9±42.7 vs. 91.3±36.7 ml) increased while mean voiding volume (146.0±24.5 vs.164.9±31.1 ml),FBC (176.2±24.3 vs.198.3±27.5 ml),MFR (8.5±1.0 vs. 10.5±1.8 ml/s),I-QOL score (8.5±1.0 vs 10.5±1.8) and bladder emptying efficiency (47.8±6.7% vs. 62.0±6.4%) declined at Month 6 (all P<0.05).During follow-ups,there were transient gross in-catheter hematuria (n=7) and urinary tract infection (n=2).No other adverse events occurred. Conclusions Injections of botulinum toxin A in detrusor and external urethral sphincter is an effective,mini-invasive and safe treatment for DOIC children.It may effectively improve the symptoms of abnormal urination and lower the risks of upper urinary tract injury.Moreover,quality of life improves after injections.Efficacy remains for at least 6 months.
References:
[1] Stav K,Shilo Y,Zisman A,et al.Comparison of lower urinary tract symptoms between women with detrusor overactivity and impaired contractility,and detrusor overactivity and preserved contractility[J].J Urol,2013,189(6):2175-2178.DOI:10.1016/j.juro.2012.11.178.
[2] Wang YL,Xu KX,Hu H,et al.Prevalence,risk factors,and impact on health related quality of life of overactive bladder in China[J].Neurourol Urodyn,2011,30(8):1448-1455.DOI:10.1002/nau.21072.
[3] Liu S,Chan L,Tse V.Clinical outcome in male patients with detrusor overactivity with impaired contractility[J].Int Neurourol J,2014,18(3):133-137.DOI:10.5213/inj.2014.18.3.133.
[4] 中华医学会泌尿外科学分会尿控学组.肉毒毒素治疗下尿路功能障碍中国专家共识[J].中华泌尿外科杂志,2021,42(6):405-410.DOI:10.3760/cma.j.cn112330-20210527-00296. Group of Urinary Control,Branch of Urology,Chinese Medical Association:Chinese Expert Consensus on Treating Lower Urinary Tract Dysfunction with Botulinum Toxin[J].Chin J Urol,2021,42(6):405-410.DOI:10.3760/cma.j.cn112330-20210527-00296.
[5] Huang YH,Chen SL.Concomitant detrusor and external urethral sphincter botulinum toxin-A injections in male spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia[J].J Rehabil Med,2022,54:jrm00264.DOI:10.2340/jrm.v54.122.
[6] Seth J,Rintoul-Hoad S,Sahai A.Urethral sphincter injection of botulinum toxin a:a review of its application and outcomes[J].Low Urin Tract Symptoms,2018,10(2):109-115.DOI:10.1111/luts.12163.
[7] 陈晖,谢克基,杨幸华,等.含三角区的逼尿肌内BTX-A重复注射术联合间歇导尿治疗成年男性脊髓损伤并NDO和尿失禁的疗效及安全性[J].中华泌尿外科杂志,2022,43(9):671-674.DOI:10.3760/cma.j.cn112330-20220304-00082. Chen H,Xie KJ,Yang XH,et al.Effect and safety of repeated trigone-including intradetrusor BTX-A injection with intermittent catheterization for male adults with NDO and urinary incontinence secondary to spinal cord injury[J].Chin J Urol,2022,43(9):671-674.DOI:10.3760/cma.j.cn112330-20220304-00082.
[8] 廖利民.尿动力学[M].第2版.北京:科学出版社,2019:266-297. Liao LM.Urodynamics[M].Edition II.Beijing:Science Press,2019:266-297.
[9] Jeong SJ,Lee M,Song SH,et al.Prevalence and urodynamic characteristics of detrusor overactivity with impaired contractility in the community-dwelling elderly with non-neurogenic lower urinary tract symptoms:Is it from a single or two Independent bladder dysfunctions?[J].Investig Clin Urol,2021,62(4):477-484.DOI:10.4111/icu.20200471.
[10] Yamamoto T,Sakakibara R,Uchiyama T,et al.Neurological diseases that cause detrusor hyperactivity with impaired contractile function[J].Neurourol Urodyn,2006,25(4):356-360.DOI:10.1002/nau.20224.
[11] 廖利民,丛惠伶,徐智慧,等.国产A型肉毒毒素治疗膀胱过度活动症的有效性和安全性:多中心、随机、双盲、安慰剂平行对照研究[J].中华泌尿外科杂志,2021,42(6):414-422.DOI:10.3760/cma.j.cn112330-20210520-00279. Liao LM,Cong HL,Xu ZH,et al.Efficacy and safety study of domestic botulinum toxin A 100U in patients with overactive bladder:a prospective,multicenter,double-blind and randomized controlled trial[J].Chin J Urol,2021,42(6):414-422.DOI:10.3760/cma.j.cn112330-20210520-00279.
[12] Bowen DK,Meyer T,Rosoklija I,et al.Botulinum toxin in patients at-risk for bladder augmentation:durable impact or kicking the can?[J].Neurourol Urodyn,2022,41(6):1406-1413.DOI:10.1002/nau.24962.
[13] Greer T,Abbott J,Breytenbach W,et al.Ten years of experience with intravesical and intrasphincteric onabotulinumtoxinA in children[J].J Pediatr Urol,2016,12(2):94.e1-94.e6.DOI:10.1016/j.jpurol.2015.06.019.
[14] 刘嘉林,刘颖,汤梁峰,等.A型肉毒杆菌毒素膀胱注射治疗儿童神经源性膀胱逼尿肌过度活动的效果评价[J].临床小儿外科杂志,2022,21(8):752-757.DOI:10.3760/cma.j.cn101785-202203025-009. Liu JL,Liu Y,Tang LF,et al.Evaluations of botulinum toxin injection into detrusor for neurogenic detrusor overactivity in children[J].J Clin Ped Sur,2022,21(8):752-757.DOI:10.3760/cma.j.cn101785-202203025-009.
[15] Wang CC,Lee CL,Kuo HC.Efficacy and safety of intravesical OnabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility[J].Toxins (Basel),2016,8(3):82.DOI:10.3390/toxins8030082.
[16] Safari S,Jamali S,Habibollahi P,et al.Intravesical injections of botulinum toxin type A for management of neuropathic bladder:a comparison of two methods[J].Urology,2010,76(1):225-230.DOI:10.1016/j.urology.2009.09.087.
[17] Hsiao SM,Lin HH,Kuo HC.Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome[J].Neurourol Urodyn,2014,33(3):331-334.DOI:10.1002/nau.22394.
[18] Marki? D,Mari?i? A,Ogui? R,et al.Transurethral bladder neck incision in women with primary bladder neck obstruction[J].Wien Klin Wochenschr,2014,126(7/8):217-222.DOI:10.1007/s00508-014-0502-z.
[19] Padmanabhan P,Nitti VW.Primary bladder neck obstruction in men,women,and children[J].Curr Urol Rep,2007,8(5):379-384.DOI:10.1007/s11934-007-0035-3.
[20] Lim SK,Quek PLC.Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia:a pilot study[J].Eur Urol,2008,53(3):620-627.DOI:10.1016/j.eururo.2007.10.001.
[21] Pascali MP,Mosiello G,Marciano A,et al.A simplified technique for botulinum toxin injections in children with neurogenic bladder[J].J Urol,2011,185(6 Suppl):2558-2562.DOI:10.1016/j.juro.2011.01.037.
[22] Hui C.Safety and efficacy of trigonal BTX-A injections for children with neurological detrusor overactivity secondary to spinal cord injury[J].J Pediatr Surg,2020,55(12):2736-2739.DOI:10.1016/j.jpedsurg.2020.05.019.
Memo
收稿日期:2023-06-28。
基金项目:国家自然科学基金(U1904208)
通讯作者:王庆伟,Email:uomn0824@126.com